Apolipoprotein C‐III predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria

We studied apolipoprotein C‐III (apoC‐III) in relation to diabetic kidney disease (DKD), cardiovascular outcomes, and mortality in type 1 diabetes.

[1]  R. Eckel,et al.  Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes. , 2020, Journal of clinical lipidology.

[2]  J. Borén,et al.  The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans , 2020, Frontiers in Endocrinology.

[3]  A. Jaffe,et al.  A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. , 2020, JAMA cardiology.

[4]  L. Rohrer,et al.  Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation , 2019, Nature Immunology.

[5]  J. Hokanson,et al.  Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes. , 2019, The Journal of clinical investigation.

[6]  S. Duggan,et al.  Volanesorsen: First Global Approval , 2019, Drugs.

[7]  M. Budoff,et al.  Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D , 2019, Journal of Lipid Research.

[8]  Jennifer K. Sun,et al.  A Signature of Circulating Inflammatory Proteins and Development of End Stage Renal Disease in Diabetes , 2019, Nature Medicine.

[9]  A. Zwinderman,et al.  Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Xiaoke Yin,et al.  Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III , 2017, Journal of the American College of Cardiology.

[11]  P. Meikle,et al.  Low-Density Lipoprotein Receptor–Dependent and Low-Density Lipoprotein Receptor–Independent Mechanisms of Cyclosporin A–Induced Dyslipidemia , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Richard G. Lee,et al.  Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes , 2016, Diabetes Care.

[13]  H. Burdett.  Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia , 2016, Annals of clinical biochemistry.

[14]  D. Gaudet,et al.  Targeting APOC3 in the familial chylomicronemia syndrome. , 2014, The New England journal of medicine.

[15]  M. Taskinen,et al.  Different Lipid Variables Predict Incident Coronary Artery Disease in Patients With Type 1 Diabetes With or Without Diabetic Nephropathy: The FinnDiane Study , 2014, Diabetes Care.

[16]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[17]  K. Hunt,et al.  Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects , 2013, Diabetes Care.

[18]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[19]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[20]  C. Forsblom,et al.  Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study , 2011, BMJ : British Medical Journal.

[21]  A. Avogaro,et al.  Endothelial Dysfunction in Diabetes , 2011, Diabetes Care.

[22]  M. Taskinen,et al.  Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[23]  M. Taskinen,et al.  Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes , 2009, Diabetologia.

[24]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[25]  Merlin C. Thomas,et al.  The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes , 2009, Diabetes.

[26]  G. Nijpels,et al.  Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study. , 2008, Clinical chemistry.

[27]  P. Libby,et al.  Apolipoprotein CIII Induces Expression of Vascular Cell Adhesion Molecule-1 in Vascular Endothelial Cells and Increases Adhesion of Monocytic Cells , 2006, Circulation.

[28]  A. Książek,et al.  A Long-Term Study of Dyslipidemia and Dyslipoproteinemia in Stable Post-Renal Transplant Patients , 2006, Renal failure.

[29]  Merlin C. Thomas,et al.  Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). , 2005, Diabetes care.

[30]  Nancy Dekki,et al.  Apolipoprotein CIII promotes Ca2+-dependent β cell death in type 1 diabetes , 2004 .

[31]  S. Bandinelli,et al.  Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[32]  M. Pfeffer,et al.  VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial , 2000, Circulation.

[33]  A. Donker,et al.  Endothelial dysfunction and pathogenesis of diabetic angiopathy. , 1997, Cardiovascular research.

[34]  M. Muggeo,et al.  Cardiovascular Disease and Its Risk Factors in IDDM in Europe , 1996, Diabetes Care.

[35]  J. Breslow,et al.  Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. , 1995, The Journal of clinical investigation.

[36]  A. Gaber,et al.  Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation. , 1994, Metabolism: clinical and experimental.

[37]  J. Harmon,et al.  Plasma Apolipoprotein C-III Levels in Children With Type I Diabetes , 1988, Southern medical journal.

[38]  John,et al.  Increased apolipoprotein C 3 drives cardiovascular risk in type 1 diabetes , 2019 .

[39]  P. Libby,et al.  Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease , 2016 .

[40]  P. Libby,et al.  Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis , 2016 .

[41]  G. Page,et al.  Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. , 2005, Journal of diabetes and its complications.